Two growth-hormone-releasing hormone (GHRH) analogues compared for research. Laboratory and preclinical reference only.
The Short Answer
CJC-1295 and Tesamorelin are both GHRH analogues that stimulate growth-hormone release, but Tesamorelin is FDA-approved for a specific clinical indication while CJC-1295 remains a research compound with a long, engineered half-life. The approval status and half-life are the two biggest differences.
Mechanism
Both peptides mimic GHRH to trigger growth-hormone secretion, but CJC-1295 is modified to bind serum albumin for a much longer half-life, whereas Tesamorelin is dosed more frequently in its approved protocol. The albumin-binding modification is CJC-1295’s defining design feature.
Research Applications
Tesamorelin is studied for visceral-fat reduction in specific patient populations, while CJC-1295 is primarily used in preclinical research on growth-hormone secretion patterns and its long-duration agonism. They are not interchangeable in study design.
- Tesamorelin: approved for visceral adiposity reduction in a defined population
- CJC-1295: research focus on long-half-life GH secretion
- Shared: both increase pulsatile growth-hormone output
Half-Life and Dosing
CJC-1295’s albumin-binding gives it a half-life measured in days, while Tesamorelin is dosed daily in its approved protocol — a practical difference that dictates study design. The dosing schedule is where protocols diverge most.
| Property | CJC-1295 | Tesamorelin |
|---|---|---|
| Class | GHRH analogue | GHRH analogue |
| Half-life | Days (albumin-bound) | ~26–38 min |
| Status | Research compound | FDA-approved (specific indication) |
| Typical dosing | Extended interval | Daily (approved protocol) |
FAQ
Q: Is CJC-1295 the same as Tesamorelin?
A: No — both are GHRH analogues, but CJC-1295 has a dramatically longer half-life from albumin binding, and Tesamorelin has an FDA-approved clinical indication. They share a class but differ in design and status.
Q: What’s CJC-1295 used for in research?
A: CJC-1295 is used in preclinical research on sustained growth-hormone secretion and the effects of long-duration GHRH agonism. It is not an approved therapeutic.
Q: What purity should CJC-1295 have?
A: Research-grade CJC-1295 should be ≥98% purity by HPLC with MS confirmation and an independent COA for the exact batch. Verify the batch number matches the report.